Targeting chemokine receptor CCR4 in adult T-cell leukemia-lymphoma and other T-cell lymphomas

Current Hematologic Malignancy Reports

Volumn 7, Issue 3, 2012, Pages 235-240

  Tobinai, Kensei ^a   Takahashi, Takeshi ^b   Akinaga, Shiro ^b  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

Adult T cell leukemia lymphoma; ATL; CCR4; Chemokine receptor; KW 0761; Mogamulizumab; Monoclonal antibody; Peripheral T cell lymphoma; PTCL

Indexed keywords

ALEMTUZUMAB; BORTEZOMIB; BRENTUXIMAB VEDOTIN; CARBOPLATIN; CHEMOKINE RECEPTOR CCR4; CYCLOPHOSPHAMIDE; DENILEUKIN DIFTITOX; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; FORODESINE; GEMCITABINE; LENALIDOMIDE; MOGAMULIZUMAB; NELARABINE; PANOBINOSTAT; PRALATREXATE; PREDNISONE; RANIMUSTINE; ROMIDEPSIN; SIPLIZUMAB; VINCRISTINE; VINDESINE; VORINOSTAT;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; FAILURE FREE SURVIVAL; FEBRILE NEUTROPENIA; HUMAN; MOLECULARLY TARGETED THERAPY; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL T CELL LYMPHOMA; PHASE 2 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RASH; T CELL LEUKEMIA; TREATMENT DURATION; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; HUMANS; LEUKEMIA-LYMPHOMA, ADULT T-CELL; LYMPHOMA, T-CELL; MOLECULAR TARGETED THERAPY; PROGNOSIS; RECEPTORS, CCR4;

EID: 84865976421     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-012-0124-3     Document Type: Article

References (46)

1. Ascani S, Zinzani PL, Gherlinzoni F, et al. Peripheral T-cell lymphomas. Clinico-pathologic study of 168 cases diagnosed according to the R.E.A.L. Classification. Ann Onco. 1997;8:583-92.
2. Anderson JR, Armitage JO, Weisenburger DD. Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project. Ann Oncol. 1998;9:717-20.
3. Nakamura S, Koshikawa T, Koike K, et al. Phenotypic analysis of peripheral T cell lymphoma among the Japanese. Acta Pathol Jpn. 1993;43:396-412.
4. Aoki R,Karube K, SugitaY, et al.Distribution ofmalignant lymphoma in Japan: analysis of 2260 cases, 2001-2006. Pathol Int. 2008;58:174-82.
5. Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumors of haematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2008.
6. National Comprehensive Cancer Network (NCCN). Non-Hodgkin's lymphomas. NCCN clinical practice guidelines in oncology. v.1.2010. Fort Washington, PA: NCCN; 2010.
7. Coiffier B, Lepage E, Brière J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med. 2002;346:235-42.
8. Friedberg JW, Cohen P, Chen L, et al. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol. 2008;26:204-10.
9. Sandlund JT, Pui CH, Santana VM, et al. Clinical features and treatment outcome for children with CD30+ large-cell non-Hodgkin's lymphoma. J Clin Oncol. 1994;12:895-8.
10. Vose J, Armitage J,Weisenburger D. International T-Cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26:4124-30.
11. Foss FM, Zinzani PL, Vose JM, et al. Peripheral T-cell lymphoma. Blood. 2011;117:6756-67.
12. Sonoda S, Li HC, Tajima K. Ethnoepidemiology of HTLV-1 related diseases: ethnic determinants of HTLV-1 susceptibility and its worldwide dispersal. Cancer Sci. 2011;102:295-301.
13. Iwanaga M, Watanabe T, Utsunomiya A, et al. Human T-cell leukemia virus type I (HTLV-1) proviral load and disease progression in asymptomatic HTLV-1 carriers: a nationwide prospective study in Japan. Blood. 2010;116:1211-9.
14. Yamaguchi K, Watanabe T. Human T lymphotropic virus type-I and adult T-cell leukemia in Japan. Int J Hematol. 2002;76 Suppl 2:240-5.
15. Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma: A report from the Lymphoma Study Group (1984-87). Br J Haematol. 1991;79:428-37.
16. Tsukasaki K, Hermine O, Bazarbachi A, et al. Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. J Clin Oncol. 2009;27:453-9.
17. Tobinai K. Clinical trials for human T-cell lymphotropic virus type I-associated peripheral T-cell lymphoma in Japan. Semin Hematol. 2010;47 Suppl 1:S5-7.
18. Yamada Y, Tomonaga M, Fukuda H, et al. A new G-CSFsupported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303. Br J Haematol. 2001;113:375-82.
19. Tsukasaki K, Utsunomiya A, Fukuda H, et al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemialymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol. 2007;25:5458-64.
20. Bazarbachi A, Plumelle Y, Carlos Ramos J, et al. Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes. J Clin Oncol. 2010;28:4177-83.
21. Waldmann TA. Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphoma. Oncogene. 2007;26:3699-703.
22. Zhang Z, Zhang M, Ravetch JV, et al. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD2 monoclonal antibody, MEDI-507. Blood. 2003;102:284-8.
23. Zhang Z, Zhang M, Goldman CK, et al. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H. Cancer Res. 2003;63:6453-7.
24. Ravandi F, Faderl S. Complete response in a patient with adult T-cell leukemia (ATL) treated with combination of alemtuzumab and pentostatin. Leuk Res. 2006;30:103-5.
25. Callens C, Moura IC, Lepelletier Y, et al. Recent advances in adult T-cell leukemia therapy: focus on a new anti-transferrin receptor monoclonal antibody. Leukemia. 2008;22:42-8.
26. Dearden CE. Role of single-agent purine analogues in therapy of peripheral T-cell lymphomas. Semin Hematol. 2006;43:S22-6.
27. Tobinai K. Current management of adult T-cell leukemia/lymphoma. Oncology (Williston Park). 2009;23:1250-6.
28. O'Connor OA, Pro B, Pinter-Brown L, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol. 2011;29:1182-9.
29. D'Ambrosio D, Iellem A, Bonecchi R, et al. Selective up-regulation of chemokine receptors CCR4 and CCR8 upon activation of polarized human type 2 Th cells. J Immunol. 1998;161:5111-5.
30. Iellem A, Mariani M, Lang R, et al. Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4(+)CD25(+) regulatory T cells. J Exp Med. 2001;194:847-53.
31. Mariani M, Lang R, Binda E, et al. Dominance of CCL22 over CCL17 in induction of chemokine receptor CCR4 desensitization and internalization on human Th2 cells. Eur J Immunol. 2004;34:231-40.
32. Ishida T, Utsunomiya A, Iida S, et al. Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcome. Clin Cancer Res. 2003;9:3625-34.
33. Nakayama T, Hieshima K, Arao T, et al. Aberrant expression of Fra-2 promotes CCR4 expression and cell proliferation in adult T-cell leukemia. Oncogene. 2008;27:3221-32.
34. Ishida T, Inagaki H, Utsunomiya A, et al. CXC chemokine receptor 3 and CC chemokine receptor 4 expression in T-cell and NK-cell lymphomas with special reference to clinicopathological significance for peripheral T-cell lymphoma, unspecified. Clin Cancer Res. 2004;10:5494-500.
35. Jones D, O'Hara C, Kraus MD, et al. Expression pattern of T-cellassociated chemokine receptors and their chemokines correlates with specific subtypes of T-cell non-Hodgkin lymphoma. Blood. 2000;96:685-90.
36. Nakagawa M, Nakagawa-Oshiro A, Karnan S, et al. Array comparative genomic hybridization analysis of PTCL-U reveals a distinct subgroup with genetic alterations similar to lymphoma-type adult Tcell leukemia/lymphoma. Clin Cancer Res. 2009;15:30-8.
37. Imai T, Nagira M, Takagi S, et al. Selective recruitment of CCR4-bearing Th2 cells toward antigen-presenting cells by the CC chemokines thymus and activation-regulated chemokine and macrophage-derived chemokine. Int Immunol. 1999;11:81-8.
38. Niwa R, Shoji-Hosaka E, Sakurada M, et al. Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma. Cancer Res. 2004;64:2127-33.
39. Ishii T, Ishida T, Utsunomiya A, et al. Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia/lymphoma. Clin Cancer Res. 2010;16:1520-31.
40. Shinkawa T, Nakamura K, Yamane N, et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem. 2003;278:3466-73.
41. Yano H, Ishida T, Imada K, et al. Augmentation of antitumour activity of defucosylated chimeric anti-CCR4 monoclonal antibody in SCID mouse model of adult T-cell leukaemia/lymphoma using G-CSF. Br J Haematol. 2008;140:586-9.
42. Ito A, Ishida T, Utsunomiya A, et al. Defucosylated anti-CCR4 monoclonal antibody exerts potent ADCC against primary ATLL cells mediated by autologous human immune cells in NOD/Shi-scid, IL-2R gamma(null) mice in vivo. J Immunol. 2009;183:4782-91.
43. Yamamoto K, Utsunomiya A, Tobinai K, et al. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J Clin Oncol. 2010;28:1591-8. This manuscript describes the results of a phase I study of mogamulizumab (KW-0761) in ATL and PTCL, showing encouraging therapeutic efficacy with acceptable toxicity profiles.
44. Yamamoto K, Tobinai K, Akinaga S, et al. Reply to R. Suzuki. J Clin Oncol. 2010;29:8356.
45. Ishida T, Joh T,UikeN, et al.Defucosylated anti-CCR4monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol. 2012;30:837-42. This manuscript describes the results of a phase II study of mogamulizumab/KW-0761 in relapsed patients with ATL, yielding a best overall response rate of 50% and median progression-free survival of 5.2 months.
46. Duvic M, Pinter-Brown L, Foss FM, et al.: Results of a phase 1/2 study for KW-0761, a monoclonal antibody directed against CC chemokine receptor type 4 (CCR4), in CTCL patients. [abstract 962]. Presented at the 52nd Annual Meeting of the American Society of Hematology. Orlando, USA; December 4-7, 2010.